Objective-Syndecan-4 (Syn4) is a heparan sulfate proteoglycan and works as a coreceptor for various growth factors. We examined whether Syn4 could be involved in the development of neointimal formation in vivo. Methods and Results-Wild-type (WT) and Syn4-deficient (Syn4 Ϫ/Ϫ ) mice were subjected to wire-induced femoral artery injury. Syn4 mRNA was upregulated after vascular injury in WT mice. Neointimal formation was attenuated in Syn4 Ϫ/Ϫ mice, concomitantly with the reduction of Ki67-positive vascular smooth muscle cells (VSMCs). Basic-fibroblast growth factor-or platelet-derived growth factor-BB-induced proliferation, extracellular signal-regulated kinase activation, and expression of cyclin D1 and Bcl-2 were impaired in VSMCs from Syn4 Ϫ/Ϫ mice. To examine the role of Syn4 in bone marrow (BM)-derived vascular progenitor cells (VPCs) and vascular walls, we generated chimeric mice by replacing the BM cells of WT and Syn4Ϫ/Ϫ mice with those of WT or Syn4 Ϫ/Ϫ mice. Syn4 expressed by both vascular walls and VPCs contributed to the neointimal formation after vascular injury. Although the numbers of VPCs were compatible between WT and Syn4 Ϫ/Ϫ mice, mobilization of VPCs from BM after vascular injury was defective in Syn4Ϫ/Ϫ mice. Conclusion-Syn4 deficiency limits neointimal formation after vascular injury by regulating VSMC proliferation and VPC mobilization. Therefore, Syn4 may be a novel therapeutic target for preventing arterial restenosis after angioplasty. oth excessive proliferation and migration of vascular smooth muscle cells (VSMCs) from arterial media to neointima and mobilization of bone marrow (BM)-derived vascular progenitor cells (VPCs) are the major causes of neointimal hyperplasia, which contributes to the development and progression of various vascular pathologies, such as atherosclerosis and restenosis after angioplasty. [1][2][3][4] Although drug-eluting stents can inhibit smooth muscle cell proliferation and reduce the rate of restenosis, 5 their clinical benefits are still limited because of the critical problems, such as causing late stent thrombosis and the need for continuing dual antiplatelet therapy. 6,7 Therefore, the elucidation of the molecular mechanisms by which neointimal hyperplasia develops after vascular injury is necessary to establish the development of novel approaches for improving the safety and efficacy of angioplasty.
See accompanying article on page 952Proliferation and migration of VSMCs after vascular injury are modulated by various components of the extracellular matrix, particularly heparin and the related heparan sulfate proteoglycans. 8 Heparan sulfate proteoglycans are distributed ubiquitously as a component of the extracellular matrix or at the cell surface. Among the heparan sulfate proteoglycans, both perlecan and syndecan-1, a member of the syndecan family that works as a coreceptor and reservoir for growth factors, cytokines, and extracellular matrix proteins through its heparan sulfate chains, 9 have been shown to inhibit VSMC proliferation and neointimal hy...